A major challenge in drug development is that all cancer patients respond differently to treatment, making it difficult to know how best to treat each patient. For the first time, a phase I trial in Oxford will investigate not only a new drug, called CXD101, but also a new test to predict which patients could be successfully treated by this class of drug.
New trial of personalised cancer treatment begins in Oxford
- 14 March 2014
The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.